Pacer Advisors
CPRX

Pacer Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Pacer Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43K Sell
1,382
-360,412
-100% -$10.6M ﹤0.01% 2069
2026
Q1 		$8.96M Sell
361,794
-31,939
-8% -$761K 0.03% 465
2025
Q4 		$9.19M Sell
393,733
-227,068
-37% -$5.06M 0.02% 513
2025
Q3 		$12.2M Sell
620,801
-24,331
-4% -$500K 0.03% 433
2025
Q2 		$14M Sell
645,132
-209,235
-24% -$4.94M 0.03% 400
2025
Q1 		$20.7M Sell
854,367
-2,101,141
-71% -$47.3M 0.05% 302
2024
Q4 		$61.7M Buy
2,955,508
+151,495
+5% +$3.25M 0.13% 174
2024
Q3 		$55.7M Sell
2,804,013
-163,562
-6% -$3.03M 0.12% 194
2024
Q2 		$46M Buy
2,967,575
+2,965,310
+130,919% +$46.2M 0.1% 214
2024
Q1 		$36.1K Buy
+2,265
New +$34.1K ﹤0.01% 3302
2023
Q2 		– Sell
-513,734
Closed -$8.52M – 3534
2023
Q1 		$8.52M Buy
+513,734
New +$8.48M 0.04% 451
2021
Q2 		– Sell
-10,206
Closed -$47K – 1441
2021
Q1 		$47K Buy
10,206
+1,598
+19% +$6.35K ﹤0.01% 1442
2020
Q4 		$29K Sell
8,608
-737
-8% -$2.48K ﹤0.01% 1463
2020
Q3 		$28K Buy
+9,345
New +$36.5K ﹤0.01% 1340

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pacer Advisors's CPRX Position: Q2 2026 in Review

Pacer Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 100% in Q2 2026, selling an estimated $10.6M and leaving 1,382 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Pacer Advisors first reported a position in CPRX in Q3 2020 and has held it in 14 quarters since. The position peaked at $61.7M in Q4 2024. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Pacer Advisors held 1,382 shares of Catalyst Pharmaceutical worth $43K as of Q2 2026.
  • Pacer Advisors sold 360,412 Catalyst Pharmaceutical shares in Q2 2026, an estimated $10.6M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2069 holding.
  • Pacer Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 14 quarters since.
  • Pacer Advisors's Catalyst Pharmaceutical position peaked at $61.7M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.